CBLI:NSD-Cleveland BioLabs Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.93

Change

-0.26 (-8.15)%

Market Cap

USD 0.11B

Volume

0.10M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Cytocom, Inc., a clinical-stage biopharmaceutical company, develops novel small molecule immunotherapies targeting cancer, autoimmune, inflammatory, and infectious diseases. Its platform, Advanced Immunomodulating Multi-receptor System (AIMS), offers noroxymorphone analogs multi-receptor modulating therapies and proenkephalin analogs multi-receptor modulating therapies. The company also has various clinical-stage development programs, including CYTO-200 for Crohn's disease, fibromyalgia, multiple sclerosis, and covid-19; CYTO-400 for hepatocellular and pancreatic cancer; and CYTO-600 for acute radiation syndrome, advanced solid tumors, and vaccine adjuvant. Cytocom, Inc. has a collaboration agreement with the La Jolla Institute for Immunology for research and development of new immune-modulating agents targeting toll-like receptors for the treatment of cancer, infectious, autoimmune, and chronic inflammatory diseases. The company is based in Fort Collins, Colorado. Address: 2537 Research Boulevard, Fort Collins, CO, United States, 80526

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-20 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-6.72 (-1.56%)

USD173.59B 50.81 42.25
BNTX BioNTech SE

-20.17 (-5.62%)

USD82.22B 18.72 15.10
REGN Regeneron Pharmaceuticals Inc

-10.99 (-1.69%)

USD69.72B 11.77 9.06
VRTX Vertex Pharmaceuticals Incorpo..

-2.63 (-1.40%)

USD48.85B 24.83 16.63
BGNE BeiGene Ltd

-4.64 (-1.15%)

USD42.80B N/A N/A
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+2.85 (+1.82%)

USD28.42B 48.74 39.11
GMAB Genmab A/S

-0.18 (-0.42%)

USD28.19B 71.63 8.17
RPRX Royalty Pharma plc

-1.67 (-4.34%)

USD23.38B 31.17 12.50
ALNY Alnylam Pharmaceuticals Inc

-6.88 (-3.61%)

USD21.80B N/A N/A

ETFs Containing CBLI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.07% 49% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.07% 49% F 25% F
Trailing 12 Months  
Capital Gain 40.19% 72% C- 59% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.19% 72% C- 57% F
Trailing 5 Years  
Capital Gain 75.44% 70% C- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.44% 70% C- 62% D-
Average Annual (5 Year Horizon)  
Capital Gain 55.47% 77% C+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.47% 77% C+ 86% B
Risk Return Profile  
Volatility (Standard Deviation) 120.99% 22% F 13% F
Risk Adjusted Return 45.84% 73% C 63% D
Market Capitalization 0.11B 20% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 177.00 7% F 7% F
Price/Book Ratio 8.37 20% F 17% F
Price / Cash Flow Ratio -45.37 88% B+ 86% B
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -31.86% 76% C 35% F
Return on Invested Capital -172.57% 7% F 4% F
Return on Assets -20.33% 62% D- 19% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.08 98% A+ 97% A+
Short Percent 0.08% 99% A+ 95% A
Beta 0.70 79% C+ 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector